‘You’ve lied, violated…’: Murphy grills Surgeon Gen nominee over undisclosed paid product promotions

Key Concepts

• Financial Disclosure: The core issue revolves around the nominee’s alleged failure to transparently disclose financial relationships with companies whose products she promoted online.
• FTC Guidelines: The Federal Trade Commission (FTC) policies regarding endorsements and disclosure of financial connections are central to the questioning.
• Conflict of Interest: Concerns are raised about potential conflicts of interest stemming from undisclosed financial ties and the nominee’s advocacy for certain products.
• Psilocybin & Psychedelics: Discussion centers on the nominee’s personal use of psychedelics and her views on psilocybin-assisted therapy.
• Alzheimer’s Research: Questions arise regarding the nominee’s statements about NIH-funded Alzheimer’s research and her stance on comprehensive research approaches.
• Modifiable Risk Factors (Alzheimer's): The importance of lifestyle and environmental factors in preventing Alzheimer's, as highlighted in the Lancet study.

Examination of Financial Disclosures & FTC Compliance

The hearing focused heavily on allegations that Dr. Means routinely violated FTC guidelines by failing to disclose financial connections with companies whose products she recommended on social media. The committee presented evidence suggesting a pattern of non-disclosure, specifically citing instances where she claimed to be “just a fan” or stated “not sponsored” while simultaneously receiving compensation.

Specific examples were detailed:

• We Natal (Prenatal Vitamin): Dr. Means allegedly began receiving compensation in the spring of 2024, yet in September 2024, she posted a video stating she had no financial relationship with the company. She also stated “Not sponsored, just love these” in October, despite receiving partnership fees and utilizing compensated clickthrough links prior to these statements.
• Function Health (Lab Testing Platform): Disclosure of her partnership with Function Health occurred less than one-third of the time she recommended their services.
• Genova Diagnostics: Sponsorship was disclosed in only two out of nine promotional posts.
• Daily Harvest: Disclosure occurred in only three out of fourteen posts.
• Zen Basil Seeds: Partnership was disclosed in only two out of thirteen recommendations.

The committee argued this constituted a “systemic” and “willful violation” of FTC rules, particularly concerning given her large online following (almost a million Instagram followers and 200,000 newsletter subscribers). The committee member stated, “It seems that in the majority of instances in which you were as a medical professional recommending a product, you were hiding the fact that you had a financial partnership.”

Dr. Means countered these claims, stating that any instances of non-disclosure were unintentional and that she had been actively working with the Office of Government Ethics to ensure full compliance. She asserted, “If in any post where I said I am not receiving money, I had not been receiving money at that time.” However, she acknowledged receiving partnership fees and utilizing compensated links. She also expressed skepticism about the data collection methods used by the committee’s staff, suggesting it was intentionally designed to create negative claims.

Discussion of Psychedelic Use & Public Health Messaging

Senator Collins raised concerns about Dr. Means’s personal use of psilocybin mushrooms, as detailed in her book Good Energy, and her encouragement of others to consider psilocybin-assisted therapy. Dr. Means began using psychedelic mushrooms in 2021, inspired by what she described as an “internal voice” urging her to “prepare” following her mother’s pancreatic cancer diagnosis.

Dr. Means clarified that her views as a private citizen differed from her potential role as Surgeon General. She stated she would not recommend psychedelic use to the American public in her official capacity, emphasizing the importance of evidence-based science and public safety. She acknowledged the emerging research on psychedelic therapies for conditions like PTSD and mental health issues, calling it “exciting” and expressing her intention to follow the research closely. She emphasized that illicit drug use remains a “monumental and severe” problem in the country.

Regarding the “internal voice” experience, Dr. Means explained it was related to her mother’s diagnosis and a period of deep meditation and prayer. She also highlighted the growing recognition of the role of spirituality in health, citing research from Columbia University demonstrating its impact on health outcomes.

Examination of Alzheimer’s Research & Modifiable Risk Factors

The hearing also addressed Dr. Means’s comments regarding NIH-funded Alzheimer’s research, specifically her claim that some research had been “fraudulent” due to replication issues with amyloid plaque research. Senator Cassidy pointed out that this claim had been largely debunked.

Dr. Means reaffirmed her support for vigorous and comprehensive Alzheimer’s research, encompassing medical, genetic, lifestyle, and environmental factors. She highlighted a 2024 Lancet study identifying 14 modifiable risk factors that could reduce Alzheimer’s dementia cases by 45%. She expressed enthusiasm for elevating this type of research, which focuses on prevention and empowerment, rather than solely on treatments for existing disease. She stated, “This isn't really the type of research that we've been hearing from the medical community. We hear a lot about drugs. We feel hear a lot about interventions that slow decline once we're sick.”

Logical Connections & Synthesis

The hearing demonstrated a clear line of inquiry focused on Dr. Means’s trustworthiness and potential conflicts of interest. The questioning regarding financial disclosures and FTC compliance served to establish a pattern of behavior that raised concerns about her integrity and adherence to ethical guidelines. The discussion of psychedelic use and Alzheimer’s research, while seemingly disparate, contributed to this overarching theme by questioning her judgment and the accuracy of her public statements.

The committee members consistently emphasized the importance of restoring trust in the medical profession, and positioned Dr. Means’s alleged actions as undermining that goal. Dr. Means consistently defended her actions, emphasizing her commitment to ethical conduct and her ongoing efforts to ensure compliance with relevant regulations.

The main takeaway is that Dr. Means faces significant scrutiny regarding her past conduct and her ability to maintain public trust if confirmed as Surgeon General. The hearing highlighted the critical importance of transparency and ethical behavior for individuals in positions of public health leadership.